6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

711 trials found

diseases per page:

Showing 1 to 10 of 711 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04147949 (ClinicalTrials.gov)	August 2022	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Effi ...	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
2	NCT05312632 (ClinicalTrials.gov)	April 5, 2022	28/3/2022	A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopain P ...	A Multi-center, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Safinamide Mesilate a ...	Parkinson Disease	Drug: Safinamide Mesilate	Eisai Korea Inc.	NULL	Recruiting	19 Years	N/A	All	199	Phase 4	Korea, Republic of
3	EUCTR2020-002754-24-DE (EUCTR)	19/01/2022	14/06/2021	Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa100 mg in ...	A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study ...	Parkinson's Disease (PD) MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinso ...	Trade Name: Ongentys 50 mg hard capsules INN or Proposed INN: Ongentys 50 mg hard capsules Other descrip ...	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
4	NCT05094050 (ClinicalTrials.gov)	January 18, 2022	20/10/2021	Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult ...	Parkinson's Disease: A Comparative Study of Levodopaand Carbidopa Bioavailability Following Foslevod ...	Parkinson's Disease	Drug: ABBV-951	AbbVie	NULL	Active, not recruiting	30 Years	N/A	All	16	Phase 1	United States
5	NCT05083260 (ClinicalTrials.gov)	January 4, 2022	23/9/2021	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's ...	Parkinson Disease	Drug: NE3107;Drug: placebo	BioVie Inc.	NULL	Completed	30 Years	80 Years	All	46	Phase 1/Phase 2	United States
6	NCT05523791 (ClinicalTrials.gov)	January 1, 2022	17/8/2022	Whey Protein Supplementation in Patients With Parkinson's Disease	Can we Add Whey Protein Supplementation in Patients With Parkinson's Disease Without Interfering Wit ...	Parkinson Disease	Dietary Supplement: Fortiral;Dietary Supplement: Mg ++	Ospedale Generale Di Zona Moriggia-Pelascini	NULL	Completed	60 Years	N/A	All	51	N/A	Italy
7	NCT04952194 (ClinicalTrials.gov)	January 1, 2022	3/6/2021	Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease	Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease	Parkinson Disease	Drug: Stalevo;Drug: Carbidopa and Levodopa Controlled Release Tablets	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	30 Years	70 Years	All	180	Phase 4	China
8	NCT04990284 (ClinicalTrials.gov)	November 29, 2021	27/7/2021	eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study ...	Parkinson Disease	Drug: Opicapone;Drug: L-DOPA /DDCI	Bial - Portela C S.A.	NULL	Recruiting	30 Years	N/A	All	100	Phase 4	Germany;Italy;Portugal;Spain;United Kingdom
9	EUCTR2019-004235-23-SE (EUCTR)	13/11/2021	24/08/2021	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-95 ...	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily ex ...	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Other ...	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Denmark;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom;J ...
10	NCT05297201 (ClinicalTrials.gov)	November 2, 2021	17/2/2022	Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia	Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potenti ...	Parkinson Disease;Dyskinesia, Medication-Induced	Drug: CPL500036 - low dose;Drug: CPL500036 - high dose;Drug: Placebo	Celon Pharma SA	National Center for Research and Development, Poland	Recruiting	50 Years	80 Years	All	108	Phase 2	Poland

First Previous1 2 3 4 5…72Next Last